How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula. Hartaj Singh on LinkedIn: https://www.linkedin.com/in/hartaj-s-35614670/ Check out Hartaj's newsletter: The Biotech Capital Compass - https://hartajsingh1.substack.com/ Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify! ...
All content for Cures & Capital is the property of Martin Slezak and Simon Birksø and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula. Hartaj Singh on LinkedIn: https://www.linkedin.com/in/hartaj-s-35614670/ Check out Hartaj's newsletter: The Biotech Capital Compass - https://hartajsingh1.substack.com/ Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify! ...
Dr. Andrée Bates on AI that works: from pilot chaos to real impact
Cures & Capital
1 hour 18 minutes
6 months ago
Dr. Andrée Bates on AI that works: from pilot chaos to real impact
In this episode, we talk to Dr. Andrée Bates, founder and CEO of Eularis, a company helping clients accelerate pharma business results through Artificial Intelligence. We explore how the biopharma industry can move beyond scattered pilots toward strategic, enterprise-wide AI integration. Drawing on decades at the forefront of AI in pharma, Dr. Bates shares practical insights on building the foundations for long-term value creation and turning AI into a true competitive advantage. We also di...
Cures & Capital
How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula. Hartaj Singh on LinkedIn: https://www.linkedin.com/in/hartaj-s-35614670/ Check out Hartaj's newsletter: The Biotech Capital Compass - https://hartajsingh1.substack.com/ Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify! ...
